Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1997 1
1998 1
2000 2
2001 2
2003 1
2007 2
2009 2
2010 2
2011 2
2012 1
2013 2
2014 7
2015 11
2016 10
2017 4
2018 5
2019 7
2020 2
2021 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP. Lee D, et al. Expert Opin Pharmacother. 2023 Apr;24(6):691-703. doi: 10.1080/14656566.2023.2195539. Epub 2023 Mar 28. Expert Opin Pharmacother. 2023. PMID: 36958727
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for patients and their care partners. ...Comprehensive search of ClinicalTrials.gov was completed from January 2017 to February 2023 using the sear …
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for pat …
Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, Kumar S, Colman S, Pollock BG, Mulsant BH, Rajji TK. Davies SJ, et al. J Psychopharmacol. 2018 May;32(5):509-523. doi: 10.1177/0269881117744996. Epub 2018 Jan 17. J Psychopharmacol. 2018. PMID: 29338602 Free PMC article.
METHODS: A multidisciplinary team created evidence-based algorithms for the treatment of behavioural and psychological symptoms of dementia. We present drug treatment algorithms for agitation and aggression associated with Alzheimer's and mixed Alzheimer …
METHODS: A multidisciplinary team created evidence-based algorithms for the treatment of behavioural and psychological symptoms of dementia. …
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Porsteinsson AP, et al. JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93. JAMA. 2014. PMID: 24549548 Free PMC article. Clinical Trial.
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. ...DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a …
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease …
When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Aga VM. Aga VM. Am J Geriatr Psychiatry. 2019 Oct;27(10):1099-1107. doi: 10.1016/j.jagp.2019.04.016. Epub 2019 May 10. Am J Geriatr Psychiatry. 2019. PMID: 31288974 Review.
Agitation is a common neuropsychiatric symptom (NPS) in the early and middle stages of Alzheimer's disease (AD) dementia, which is difficult to treat and causes much distress. ...However, concerns about the cardiac side-effects of citalopram hav …
Agitation is a common neuropsychiatric symptom (NPS) in the early and middle stages of Alzheimer's disease (AD) …
Agitation and aggression in people with Alzheimer's disease.
Ballard C, Corbett A. Ballard C, et al. Curr Opin Psychiatry. 2013 May;26(3):252-9. doi: 10.1097/YCO.0b013e32835f414b. Curr Opin Psychiatry. 2013. PMID: 23528917 Review.
PURPOSE OF REVIEW: Agitation and aggression commonly arise in people with Alzheimer's disease (AD) and other dementias. ...Suggested pharmacological alternatives with the most promising preliminary evidence include memantine, carbamazepine, citalopr …
PURPOSE OF REVIEW: Agitation and aggression commonly arise in people with Alzheimer's disease (AD) and other dem …
Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
Gallagher D, Herrmann N. Gallagher D, et al. Neurodegener Dis Manag. 2015;5(1):75-83. doi: 10.2217/nmt.14.46. Neurodegener Dis Manag. 2015. PMID: 25711456 Review.
Agitation and aggression are prevalent in Alzheimer's disease and have significant consequences for the patient, caregiver and care system more generally. We briefly discuss the epidemiology and etiology of agitation and aggression in Alzheim …
Agitation and aggression are prevalent in Alzheimer's disease and have significant consequences for the patient, …
Citalopram for agitation in Alzheimer's disease: design and methods.
Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group. Drye LT, et al. Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1. Alzheimers Dement. 2012. PMID: 22301195 Free PMC article. Clinical Trial.
BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limite …
BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is as …
Advancements in the treatment of agitation in Alzheimer's disease.
Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Antonsdottir IM, et al. Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422. Expert Opin Pharmacother. 2015. PMID: 26159445 Review.
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are associated with significant negative outcomes for patients and their caregivers. ...A review of some of these clinical trials was completed: dextromethorphan/quinidine, scyllo-inosi …
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are associated with significant negative outc …
64 results